[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/pages/docs/Risk/index.md) >> Individual ID:PBN__Risk_19021 

# __Limited utilization of ai technology in clinical trials and medicine development may slow down the process of achieving precise results and accelerating medicine and vaccine development.__

## Articles mentionning the risk

* [Madurai_elavarasan_restructured_2020](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_664.md)

## Mitigations of this risk

* [Increase the use of ai technology for clinical trial monitoring and medicine development to accelerate the process and attain precise results.](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_20993.md)

## Name of the risk

Slower progress in clinical trials and medicine development, potentially delaying effective healthcare solutions.

## People affected by this risk

* [Healthcare professionals](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_2.md)
* [Researchers](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_32.md)

## Stakeholders who can mitigate this risk

* [Pharmaceutical companies](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_413.md)
* [Research institutions](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_124.md)

## Technologies linked to the risk

* [Ai algorithms for clinical trial monitoring](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_21325.md)
* [Machine learning models for drug effects prediction](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_21326.md)

## This Risk belongs to this RiskGroup

* [Technological risks](https://github.com/mm80843/T3.5/blob/pages/RiskGroup/PBN__RiskGroup_8.md)

## This Risk belongs to this RiskSubgroup

* [Healthcare infrastructure and technology adoption risks](https://github.com/mm80843/T3.5/blob/pages/RiskSubgroup/PBN__RiskSubgroup_45.md)

